EP Patent

EP1889609A2 — Immune response modifier foam formulations

Assigned to Meda AB · Expires 2008-02-20 · 18y expired

What this patent protects

The present invention provides a pharmaceutical foam formulation. Generally, the formulation includes a therapeutically effective amount of imiquimod, sotirimod or resiquimod and a fatty acid.

USPTO Abstract

The present invention provides a pharmaceutical foam formulation. Generally, the formulation includes a therapeutically effective amount of imiquimod, sotirimod or resiquimod and a fatty acid.

Drugs covered by this patent

minocycline-hydrochloride (MINOCYCLINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP1889609A2
Jurisdiction: EP
Classification: —
Expires: 2008-02-20
Drug substance claim: No
Drug product claim: No
Assignee: Meda AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.